Venus Concept, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92332W2044
USD
1.94
0.12 (6.59%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Venus Concept, Inc. stock-summary
stock-summary
Venus Concept, Inc.
Pharmaceuticals & Biotechnology
Venus Concep, Inc., formerly Restoration Robotics, Inc., develops and manufactures devices for the medical aesthetic market. The Company offers a range of products and services under various brands, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, Venus Heal, Venus Skin and Venus Bliss. It offers a product portfolio of minimally invasive and non-invasive medical aesthetic technologies in over 60 countries and 29 direct markets. Its hair restoration division includes NeoGraft, an automated hair restoration system that facilitates the harvesting of follicles during a follicular unit extraction (FUE) process. Venus Viva includes NanoFractional Radio Frequency (RF) and SmartScan technology. It offers aesthetic products for the treatment of face, neck and body. Venus Fiore is designed with three applicators to address internal vaginal health restoration, labia skin tightening and mons pubis reduction.
Company Coordinates stock-summary
Company Details
235 Yorkland Blvd Suite 900 , TORONTO ON : M2J 4Y8
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 3 Schemes (0.94%)

Foreign Institutions

Held by 7 Foreign Institutions (0.25%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Domenic Serafino
Chief Executive Officer, Director
Mr. Keith Sullivan
Director
Mr. Scott Barry
Independent Director
Dr. Garheng Kong
Independent Director
Louise Lacchin
Independent Director
Mr. Fritz LaPorte
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
16 Million
(Quarterly Results - Jun 2025)
Net Profit:
-12 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 4 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

13.17

stock-summary
Return on Equity

-1,636.18%

stock-summary
Price to Book

1.80